Key PointsDupixent global quarterly net sales grew 35% year over year to $6.5 billion.

Regeneron: 3 Key Takeaways for Long-Term Investors

The S&P 500 Index ($SPX ) (SPY ) fell -1.82% on Friday, the Dow Jones Industrial Average ($DOWI ) (DIA ) fell -1.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) fell -3.46%.  December E-mini S&P futures (ESZ26 ) fell -1.76%, and December E-mini Nasdaq futures (NQZ26 ) fell...

Stocks Fall Sharply on Intel and Amazon Sell-offs and Crypto Heist

Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Kroger Co (Symbol: KR), where a total volume of 37,954 contracts has been traded thus far today, a contract volume which is representative of approximately 3.8 mi

Noteworthy Friday Option Activity: KR, IBKR, REGN

The S&P 500 Index ($SPX ) (SPY ) is down -1.26%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.52%.  December E-mini S&P futures (ESZ26 ) are down -1.33%, and December E-mini Nasdaq futures (NQZ26...

The Franklin Systematic Style Premia ETF is seeing unusually high volume in afternoon trading Friday, with over 2.8 million shares traded versus three month average volume of about 124,000.  Shares of FLSP were up about 0.7% on the day.

Components of that ETF with the highest v

Friday's ETF with Unusual Volume: FLSP  

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) reported a 36% year-over-year increase in third-quarter 2026 revenue to $5.116 billion, supported by strong commercial performance and higher Sanofi collaboration revenue.

Regeneron Q3 Revenue Rises 36%; Pipeline Advances, FDA Catalysts Ahead; Stock Up 

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Regeneron Pharmaceuticals, Inc. News